Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Conditions
Brief summary
This phase I/II trial is studying the side effects and best dose of cixutumumab when given together with temsirolimus and to see how well they work in treating patients with breast cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other places in the body. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways by targeting certain cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may be a better treatment for breast cancer.
Detailed description
PRIMARY OBJECTIVES: I. To establish the recommended dose level for the phase II trial. (Phase I) II. To examine the safety profile of this combination in patients with metastatic breast cancer. (Phase I) III. To assess the anti-tumor activity (in terms of overall response rate) and toxicity profile of IMC-A12 (cixutumumab) in combination with temsirolimus in patients with metastatic breast cancer. (Phase II) SECONDARY OBJECTIVES: I. To estimate the progression-free survival (PFS) and overall survival distributions (as well as the 6-month PFS rate). II. To evaluate the in vivo mechanisms of action of temsirolimus in combination with IMC-A12 and to examine potential biomarker predictors of treatment response. OUTLINE: This is a phase I, dose-escalation study of cixutumumab followed by a phase II study. Patients receive temsirolimus intravenously (IV) over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 (cixutumumab is given on days 8, 15, and 22 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically for up to 2 (phase I) or 5 (phase II) years.
Interventions
BIOLOGICALCixutumumab
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
OTHERPharmacological Study
Correlative studies
DRUGTemsirolimus
Given IV
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosis of breast cancer with diagnosis of metastatic or locally recurrent disease (locally recurrent disease should be stage IV e.g. chest wall involvement) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 (Karnofsky \>= 80%) * Life expectancy of \> 12 weeks * Capable of understanding investigational nature, potential risks and benefits of the study and able to provide written informed consent * Negative serum pregnancy test =\< 7 days of registration for women of childbearing potential: * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study therapy and for 3 months after the last dose of IMC-A12 and CCI-779 (temsirolimus) * Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Nursing women must be willing to discontinue nursing; NOTE: breastfeeding should be discontinued if the mother is treated with CCI-779 and IMC-A12 * Absolute neutrophil count \>= 1,500/mcL * Hemoglobin \>= 8.5 g/dL * Platelets \>= 100,000/mcL * Total bilirubin =\< 1.5 X institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional ULN (=\< 5 X institutional ULN if liver function test \[LFT\] elevations due to liver metastases) * Creatinine =\< 1.5 X institutional ULN OR creatinine clearance \>= 60 mL/min/1.73\^2 for patients with creatinine \> institutional ULN * Fasting serum cholesterol =\< 350 mg/dL (9.0 mmol/L) * Fasting triglycerides =\< 400 mg/dL (4.56 mmol/L) * Albumin \>= 3.4 mg/dL * Fasting or non fasting serum glucose \< 120 mg/dL * Hemoglobin A1c (HbA1c) (for all patients with a history of diabetes mellitus) \< 8% * Phase I only: Any number of prior therapy regimens is allowed * Phase II only: Measurable disease is required for the Phase II portion of the study; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques (computed tomography \[CT\], magnetic resonance imaging \[MRI\], x-ray) or as \>= 10 mm with spiral CT scan * Phase II only: =\< two and at least one prior chemotherapy regimens in the setting of metastatic or locally recurrent (stage IV chest wall involvement) disease are required
Exclusion criteria
* Phase I patients only: Patients with base line diabetes requiring oral hypoglycemics or insulin * Phase II patients only: Poorly controlled diabetes mellitus; NOTE: patients with a history of diabetes mellitus on oral hypoglycemics or insulin are allowed to participate, provided that their fasting blood glucose is \< 120 mg/dL and that they are on a stable dietary or therapeutic regimen for this condition * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception (hormonal agents are not allowed and oral contraceptives are not acceptable for contraception) * Receiving hormonal agents used for the treatment of breast cancer with the exception that premenopausal women who have been on a gonadotropin-releasing hormone (GnRH) agonist and subsequently progressed may, at the discretion of the treating physician, continue on the GnRH agonist * Any of the following prior therapies: * Systemic anti-cancer therapy =\< 3 weeks prior to registration * Radiation therapy =\< 2 weeks prior to registration * Prior invasive non-breast malignancy, except for adequately treated basal or squamous cell carcinoma of the skin or other cancer from which the patient has been disease free for \>= 5 years * Known hypersensitivity reactions to macrolide antibiotics (such as erythromycin, clarithromycin, and azithromycin); allergic reactions attributed to compounds of similar chemical or biologic composition to IMC-A12, or temsirolimus * Prior treatment with agents targeting the insulin-like growth factor-I receptor (IGF-IR)/insulin-like growth factors (IGFs) or phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (Akt)/mechanistic target of rapamycin (mTOR) pathway * Receiving any other investigational agents or herbal preparations * Patients may not be taking oral corticosteroids except for replacement for adrenal insufficiency * Uncontrolled brain metastases; Note: brain metastases are not permitted on study unless the metastases have been treated by surgery or radiotherapy, and the patient has been neurologically stable and off of steroids for \>= 12 weeks * Known human immunodeficiency virus (HIV)-positive patients who have cluster of differentiation (CD)4 counts below the normal range or who are on anti-retroviral therapy that may interfere with the metabolism of temsirolimus * Uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Uncontrolled symptomatic cardiac arrhythmia * Psychiatric illness/social situations that would limit compliance with study requirements * Receiving enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, carbamazepine, phenobarbital) or any other cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin or St. John's wort
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Dose Level for Phase II Testing (RPTD) (Phase I) | During first course | The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs. The number of patients in each cohort reporting a DLT is reported. Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible, probably, or definite and fulfilling one of the following criteria: * Any grade 4 hematologic toxicity * Hyperglycemia that cannot be stably controlled with diabetic medication * Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia, hypophosphatemia, and hypokalemia) |
| Tumor Response Rate (TRR) (Complete Response [CR] or Partial Response [PR]) by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II) | Up to 5 years | A response is defined as a disease burden that meets the RECIST criteria for Complete Response (CR) or Partial Response (PR) on 2 consecutive evaluations at least 6-8 weeks apart. Complete Response (CR): All of the following must be true: 1. Disappearance of all target and non-target lesions. 2. Each target lymph node must have reduction in short axis to \<1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline measures. The rate is calculated by dividing the number of patients with a CR or PR by the number of evaluable patients. A ninety percent confidence interval for the true tumor response rate will be calculated using the Duffy-Santer approach. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) (Phase II) | Time from registration to documentation of disease progression, up to 5 years | Progression free survival is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred. In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression on the last day of therapy was administered. The distribution of progression-free survival times will be estimated using the Kaplan-Meier method.The distribution of PFS times will be estimated using the Kaplan-Meier method. |
| Adverse Events Graded Using the NCI CTCAE Version. 3 (Phase II) | Up to 5 years | Adverse events will be graded using the NCI-CTCAE v3.0 coding scheme. The maximum grade for each adverse event considered to be 'at least possibly related to treatment' will be recorded. Frequency tables will be constructed and the number of patients reporting an adverse event of grade 3 or higher at least possibly related to treatment will be reported. |
| Survival Time (Phase II) | Time from registration to death due to any cause | Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. |
| Progression Free Survival Rate | At 6 months | Progression free survival (PFS) is defined as the time from registration to documentation of disease progression. A point and interval estimate of the 6 month PFS rate will be obtained using the Kaplan-Meier method. |
| Duration of Response (Phase II) | Up to 5 years | Duration of response is defined for all evaluable patients with changes in disease burden that met the RECIST criteria for CR or PR on 2 consecutive evaluations at least 6-8 weeks apart as the date at which the CR or PR to the date progression is documented. The distribution of response durations will be estimated using the Kaplan-Meier method. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1 * 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22
* 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 3 |
| Dose Level -1 * 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22
* 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 2 |
| Dose Level -2 * 15 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22
* 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 7 |
| Dose Level -2A * 15 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22
* 4 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 6 |
| Dose Level -2B * 15 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22
* 5 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 8 |
| Phase II Phase II patients receive the recommended phase II dose determined in the phase I portion.
* 15 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
* 4 mg/kg cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | 22 |
| Total | 48 |
Baseline characteristics
| Characteristic | Dose Level 1 | Dose Level -1 | Dose Level -2 | Dose Level -2A | Dose Level -2B | Phase II | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 35 years | 68 years | 49 years | 53 years | 48.5 years | 57 years | 48.5 years |
| Region of Enrollment United States | 3 participants | 2 participants | 7 participants | 6 participants | 8 participants | 22 participants | 48 participants |
| Sex: Female, Male Female | 3 Participants | 2 Participants | 7 Participants | 6 Participants | 8 Participants | 22 Participants | 48 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 3 / 3 | 2 / 2 | 7 / 7 | 6 / 6 | 8 / 8 | 22 / 22 |
| serious Total, serious adverse events | 0 / 3 | 1 / 2 | 1 / 7 | 3 / 6 | 3 / 8 | 7 / 22 |
Outcome results
Primary
Recommended Dose Level for Phase II Testing (RPTD) (Phase I)
The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs. The number of patients in each cohort reporting a DLT is reported. Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible, probably, or definite and fulfilling one of the following criteria: * Any grade 4 hematologic toxicity * Hyperglycemia that cannot be stably controlled with diabetic medication * Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia, hypophosphatemia, and hypokalemia)
Time frame: During first course
Population: Patients registered to the Phase I portion of the protocol were analyzed for this endpoint. One patient in Dose Level -1, one patient in Dose Level -2, and two patients in Dose Level -2B discontinued study treatment during Cycle 1 for reasons unrelated to toxicity and were excluded from this endpoint.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Level 1 | Recommended Dose Level for Phase II Testing (RPTD) (Phase I) | 2 DLTs |
| Dose Level -1 | Recommended Dose Level for Phase II Testing (RPTD) (Phase I) | 1 DLTs |
| Dose Level -2 | Recommended Dose Level for Phase II Testing (RPTD) (Phase I) | 1 DLTs |
| Dose Level -2A | Recommended Dose Level for Phase II Testing (RPTD) (Phase I) | 0 DLTs |
| Dose Level -2B | Recommended Dose Level for Phase II Testing (RPTD) (Phase I) | 3 DLTs |
Primary
Tumor Response Rate (TRR) (Complete Response [CR] or Partial Response [PR]) by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)
A response is defined as a disease burden that meets the RECIST criteria for Complete Response (CR) or Partial Response (PR) on 2 consecutive evaluations at least 6-8 weeks apart. Complete Response (CR): All of the following must be true: 1. Disappearance of all target and non-target lesions. 2. Each target lymph node must have reduction in short axis to \<1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline measures. The rate is calculated by dividing the number of patients with a CR or PR by the number of evaluable patients. A ninety percent confidence interval for the true tumor response rate will be calculated using the Duffy-Santer approach.
Time frame: Up to 5 years
Population: One patient registered to the Phase II portion of the study was not eligible for this endpoint due to eligibility criteria not being met.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Level 1 | Tumor Response Rate (TRR) (Complete Response [CR] or Partial Response [PR]) by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II) | 0 percentage of patients with response |
Secondary
Adverse Events Graded Using the NCI CTCAE Version. 3 (Phase II)
Adverse events will be graded using the NCI-CTCAE v3.0 coding scheme. The maximum grade for each adverse event considered to be 'at least possibly related to treatment' will be recorded. Frequency tables will be constructed and the number of patients reporting an adverse event of grade 3 or higher at least possibly related to treatment will be reported.
Time frame: Up to 5 years
Population: All patients that received protocol treatment were evaluable for this endpoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dose Level 1 | Adverse Events Graded Using the NCI CTCAE Version. 3 (Phase II) | Grade 3+ Adverse Event | 8 participants |
| Dose Level 1 | Adverse Events Graded Using the NCI CTCAE Version. 3 (Phase II) | Grade 4+ Adverse Event | 1 participants |
Secondary
Duration of Response (Phase II)
Duration of response is defined for all evaluable patients with changes in disease burden that met the RECIST criteria for CR or PR on 2 consecutive evaluations at least 6-8 weeks apart as the date at which the CR or PR to the date progression is documented. The distribution of response durations will be estimated using the Kaplan-Meier method.
Time frame: Up to 5 years
Population: No patients were eligible for this endpoint.
Secondary
Progression Free Survival (PFS) (Phase II)
Progression free survival is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred. In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression on the last day of therapy was administered. The distribution of progression-free survival times will be estimated using the Kaplan-Meier method.The distribution of PFS times will be estimated using the Kaplan-Meier method.
Time frame: Time from registration to documentation of disease progression, up to 5 years
Population: One patient registered to the Phase II portion of the study was not eligible for this endpoint due to eligibility criteria not being met.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1 | Progression Free Survival (PFS) (Phase II) | 2.0 months |
Secondary
Progression Free Survival Rate
Progression free survival (PFS) is defined as the time from registration to documentation of disease progression. A point and interval estimate of the 6 month PFS rate will be obtained using the Kaplan-Meier method.
Time frame: At 6 months
Population: One patient registered to the Phase II portion of the study was not eligible for this endpoint due to eligibility criteria not being met.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Level 1 | Progression Free Survival Rate | 14.3 percentage of patients |
Secondary
Survival Time (Phase II)
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time frame: Time from registration to death due to any cause
Population: One patient registered to the Phase II portion of the study was not eligible for this endpoint due to eligibility criteria not being met.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1 | Survival Time (Phase II) | 10.1 months |